Skip to main content

Rakovina Therapeutics Inc(RKV-X)
TSX Venture

Today's Change
Delayed Last Update

Rakovina Therapeutics Announces Non-dilutive Financial Contributions to Support Lead Optimization of Novel Anti-cancer Agents

Globe Newswire - Tue Dec 21, 2021

VANCOUVER, British Columbia, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, today announced that the Company is receiving advisory services and research and development funding of up to $56,803 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) and up to $63,750 from MITACS.  

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe